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Summary
 
The cytotoxicity of reactive oxygen intermediates (ROIs) has been implicated in the destruc-
tion of pancreatic 
 
b 
 
cells in insulin-dependent diabetes mellitus (IDDM). Thioredoxin (TRX),
a redox (reduction/oxidation)-active protein, has recently been shown to protect cells from
oxidative stress and apoptosis. To elucidate the roles of oxidative stress in the development of
autoimmune diabetes in vivo, we produced nonobese diabetic transgenic mice that overexpress
TRX in their pancreatic 
 
b 
 
cells. In these transgenic mice, the incidence of diabetes was mark-
edly reduced, whereas the development of insulitis was not prevented. Moreover, induction of
diabetes by streptozotocin, an ROI-generating agent, was also attenuated by TRX overexpres-
sion in 
 
b 
 
cells. This is the first direct demonstration that an antioxidative and antiapoptotic pro-
tein protects 
 
b 
 
cells in vivo against both autoimmune and drug-induced diabetes. Our results
strongly suggest that oxidative stress plays an essential role in the destruction of 
 
b 
 
cells by infil-
trating inflammatory cells in IDDM.
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I
 
nsulin-dependent diabetes mellitus (IDDM)
 
1
 
 is caused by
the autoimmune destruction of insulin-producing pan-
creatic 
 
b 
 
cells (1). By the clinical onset of this disease, 
 
b
 
cells are almost completely gone, requiring affected indi-
viduals to inject insulin daily to sustain their lives. Non-
obese diabetic (NOD) mice spontaneously develop au-
toimmune diabetes with remarkable similarity to human
IDDM (2; for a review, see reference 3). A common
pathological feature is the infiltration of inflammatory cells
into the islets, termed insulitis, followed by the selective
destruction of 
 
b 
 
cells. Infiltrating cells are composed of T
and B lymphocytes, macrophages, and NK cells, among
which T cells and macrophages are believed to play the
major role in 
 
b
 
 cell destruction. However, the molecular
mechanisms of 
 
b
 
 cell destruction by these infiltrating cells
are poorly understood. Elucidation of these mechanisms is
important not only for understanding the pathogenesis of
IDDM and other autoimmune diseases, but also for devel-
oping effective means of preventing these diseases. Several
reports have suggested that locally produced reactive oxy-
gen intermediates (ROIs) are involved in these effector
mechanisms of 
 
b
 
 cell destruction (4–9). In vitro, ROIs
such as nitric oxide (NO), hydroxyl radical (OH
 
?
 
), hydro-
gen peroxide (H
 
2
 
O
 
2
 
), and superoxide radical (O
 
2
 
2
 
?
 
) were
shown to be induced in 
 
b 
 
cells by cytokines such as IL-1,
IFN-
 
g
 
, and TNF-
 
a
 
, which are known to be secreted by T
cells and macrophages that infiltrate the islets (5–9). ROIs,
either administered exogenously or induced in 
 
b 
 
cells by
cytokines, have been shown to cause the destruction of 
 
b
 
cells in vitro, and apoptosis has recently been suggested to
be the mechanism involved (10–14). Among endocrine
cells in pancreatic islets, insulin-producing cells appear par-
ticularly vulnerable to oxidative stress, probably due to
their low levels of key enzymes that scavenge ROIs (15–
19). Therefore, the targeted expression of antioxidative and
antiapoptotic molecules in pancreatic 
 
b 
 
cells would be ex-
pected to protect them from destruction and to prevent the
development of IDDM.
Thioredoxin (TRX) is a low molecular mass (
 
z
 
12 kD)
redox (reduction/oxidation)-active protein found in both
prokaryotic and eukaryotic cells (for a review, see reference
 
1
 
Abbreviations used in this paper:
 
 B6, C57BL/6J; IDDM, insulin-dependent
diabetes mellitus; NO, nitric oxide; NOD, nonobese diabetic; ROI, reac-
tive oxygen intermediate; RT, reverse transcription; STZ, streptozotocin;
TRX, thioredoxin; hprt, hypoxanthine-guanine phosphoribosyl trans-
ferase.
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20). This protein has a conserved active site containing cys-
teine residues that are reversibly reduced by the NADPH-
dependent seleno-flavoprotein, thioredoxin reductase (21).
TRX, originally studied as a reducing cofactor for ribonu-
cleotide reductase (22), is one of the essential proteins in
DNA synthesis and repair (23–25). Recent studies showed
that TRX is induced by various types of stress, such as viral
infection, ischemic insult, UV light, x-ray irradiation, and
H
 
2
 
O
 
2
 
, that it acts as a scavenger of ROIs, and that it can re-
pair proteins oxidized by ROIs (for a review, see references
20 and 26). In vitro studies have demonstrated a protective
effect of TRX against the cytotoxicity of ROIs (26). An
augmented expression of TRX is often observed in neo-
plastic cells (26, 27) and appears to attenuate the cytotoxicity
of ROI-generating antineoplastic agents such as cis-
diamminedichloroplatinum (II) (CDDP), adriamycin, etopo-
side, and mitomycin C (28, 29). TRX is also involved in
the intracellular signaling that combats oxidative stress and
apoptosis (26) through the regulation of a class of transcrip-
tion factors related to the growth and apoptosis of cells (for
a review, see references 30 and 31), such as nuclear factor
 
k
 
B, activator factor 1 (AP-1), and nuclear redox factor 1
(Ref-1) (24, 26, 32–34).
To directly assess the implications of oxidative stress in
pancreatic 
 
b
 
 cell destruction in autoimmune diabetes, we
have generated NOD transgenic mice with targeted over-
expression of the antioxidative protein, TRX, in pancreatic
 
b 
 
cells. The protective effect of TRX against 
 
b
 
 cell de-
struction was also tested in experimental diabetes induced
by the ROI-generating agent, streptozotocin (STZ). Pan-
creatic 
 
b 
 
cells were significantly protected from destruction
in both models, indicating the involvement of oxidative
stress and apoptosis in the destruction of 
 
b 
 
cells in autoim-
mune as well as STZ-induced diabetes.
 
Materials and Methods
 
Construction of the TRX Transgene.
 
The Ins-TRX transgene
(Fig. 1) consisted of the human insulin promoter (35), the rabbit
 
b 
 
globin gene sequences from the second exon to the polyadenyl-
ation signal, and human TRX cDNA inserted at the unique
EcoRI site in the 
 
b 
 
globin sequences.
 
Generation of NOD Transgenic Mice.
 
The Ins-TRX transgene
cassette was purified and microinjected into the pronuclei of one-
cell embryos of NOD mice (CLEA Japan Inc., Tokyo, Japan) as
described previously (36). Founders (F0) of generated NOD
transgenic mice were identified by PCR analysis of tail DNA.
The primers used for transgenic mouse screening were as follows:
forward 5
 
9
 
-GCTGGTTATTGTGCTGTCTC-3
 
9
 
 and reverse
5
 
9
 
-TCATCCACATCTACTTCAAGGA-3
 
9
 
. These primers am-
plify the transgene sequences between the third exon of the 
 
b
 
globin gene and human TRX cDNA. Transgenic mice were
bred with NOD mice. Male NOD transgenic mice were also
mated with female C57BL/6J (B6) mice (CLEA Japan Inc.) to
produce (NOD 
 
3 
 
B6) F1 mice. Transgenic mice were screened
by PCR. Nontransgenic littermates were used as controls.
 
Reverse Transcription PCR Analysis.
 
RNA was extracted from
major organs of NOD transgenic mice by the guanidine thiocy-
anate-cesium chloride centrifugation method (37). Complemen-
tary DNA was synthesized using oligo dT and reverse tran-
scriptase Superscript II (GIBCO BRL, Gaithersburg, MD). The
Ins-TRX gene expression was analyzed by reverse transcription
(RT)-PCR with the following primers: forward 5
 
9
 
-GGATCCT-
GAGAACTTCAGG-3
 
9
 
 and reverse 5
 
9
 
-TCATCCACATCTA-
CTTCAAGGA-3
 
9
 
 (see Fig. 1). To standardize the amount of
mRNA in each sample, RT-PCR of hypoxanthine-guanine
phosphoribosyl transferase (hprt) mRNA was performed in paral-
lel. The primers for hprt mRNA detection were as follows:
forward 5
 
9
 
-CTCGAAGTGTTGGATACAGG-3
 
9
 
 and reverse
5
 
9
 
-TGGCCTATAGGCTCATAGTG-3
 
9
 
. These primers were
designed to encompass intron sequences so that the possible PCR
products from the contaminating genomic DNA could be distin-
guished.
 
Isolation of Pancreatic Islets.
 
8-wk-old (NOD 
 
3 
 
B6) F1 trans-
genic mice, their nontransgenic littermates, and BALB/c mice
(CLEA Japan Inc.) were anesthetized with an intraperitoneal injec-
tion of pentobarbital. Pancreatic islets were isolated by stationary
collagenase (Sigma Chemical Co., St. Louis, MO) digestion of
the pancreas, followed by Ficoll 400 (Amersham Pharmacia Bio-
tech, Uppsala, Sweden) density gradient purification (38).
 
Western Blotting.
 
Isolated islets and dissected pancreata were
lysed in lysis buffer (0.15 M NaCl, 10 mM Tris-HCl, pH 7.4, and
1% NP-40) with a protease inhibitor, PMSF, and were appropri-
ately diluted with cold PBS for immunoblotting. Protein concen-
tration was determined using a protein assay kit (Bio-Rad Labo-
ratories, Hercules, CA). The lysates were incubated at 100
 
8
 
C for
5 min with a third volume of the sample buffer (75 mM Tris-
HCl, pH 6.8, 6% SDS, 15% glycerol, 15% 2-ME, and 0.015%
bromophenol blue). These samples were subjected to electro-
phoresis on an SDS/15% polyacrylamide gel and electrophoreti-
cally transferred onto a polyvinylidene difluoride membrane
(Millipore Corp., Bedford, MA). To assess the levels of human
TRX expression, known amounts of recombinant human TRX
(
 
.
 
95% pure) prepared from human TRX–producing 
 
Escherichia
coli
 
 (39) were simultaneously loaded on the gel. Mouse anti–
human TRX mAb provided by Fujirebio Inc. (Tokyo, Japan)
was used as a probe to detect human TRX. Endogenous murine
TRX was detected using rabbit anti–murine TRX polyclonal Ab
raised against a synthetic polypeptide of the COOH-terminal 10
amino acid residues of murine TRX. This Ab recognized murine
TRX but not human TRX (J. Yodoi, unpublished data). The
second Ab was rabbit anti–mouse IgG Ab or goat anti–rabbit IgG
Ab conjugated with horseradish peroxidase (both from Zymed
Laboratories, Inc., South San Francisco, CA). Human and murine
TRX were visualized using an ECL detection kit (Amersham
Pharmacia Biotech).
 
Insulin Secretion for Islets.
 
Isolated islets of 12-wk-old (NOD 
 
3
 
B6) F1 transgenic mice (line 90, female) and their nontransgenic
littermates were measured for insulin secretion according to the
Figure 1. The construction of the Ins-TRX transgene. The transgene
contains the insulin promoter, an intron from the rabbit b globin gene,
human TRX cDNA, and a poly A signal from the rabbit b globin gene.
The DNA positions to which the primers for RT-PCR analysis anneal
are shown. 
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batch incubation method (40). Each batch of 10 islets was incu-
bated at 37
 
8
 
C for 3 h in Krebs-Ringer solution containing 0.3%
BSA with 3 different glucose concentrations. Five batches of
transgenic and nontransgenic islets were simultaneously tested at
each glucose concentration (5, 10, and 25 mM). After removal
of the islets, the insulin concentration of each batch was deter-
mined using a mouse insulin ELISA kit (Seikagaku Corp., Tokyo,
Japan).
 
Diagnosis of Diabetes.
 
Female NOD transgenic mice (F2, F3)
and their nontransgenic littermates were monitored from 12 wk
of age with weekly measurements of urine glucose using TesTape
(Eli Lilly and Company, Indianapolis, IN). When mice were glu-
cosuric for two consecutive weeks, they were diagnosed as dia-
betic.
 
Evaluation of Insulitis.
 
Pancreata were removed from 12-wk-
old female NOD transgenic mice (line 90,
 
 n 
 
5 
 
10) and their
TRX-negative littermates (
 
n
 
 
 
5 
 
8), and were fixed with 20% for-
malin. After paraffin-embedded fixation, 3-
 
m
 
m slices of each pan-
creas were prepared for hematoxylin and eosin staining. 25 islets
of each pancreas were randomly chosen for microscopic examina-
tion of insulitis. According to the classification system of Kura-
sawa et al. (41), each islet was scored as follows: 
 
0
 
, an islet with-
out infiltration; 
 
1
 
, 
 
,
 
25% area of an islet was occupied by
immunocytes; 
 
2
 
, 
 
$
 
25 and 
 
,
 
50%; 
 
3
 
, 
 
$
 
50%.
 
Production of STZ-induced Diabetic Mice.
 
STZ (Wako Pure Chem-
ical Industries Ltd., Osaka, Japan) was dissolved in 0.05 M citrate
buffer (pH 4.5; reference 42), and immediately injected intraperi-
toneally into 8-wk-old (NOD 
 
3 
 
B6) F1 transgenic mice and
their TRX-negative littermates at a dose of 250 mg/kg. These
mice had been starved for 18 h before STZ treatment, and were
then fed ad libitum.
 
Measurements of Blood Glucose Levels and Pancreatic Insulin Con-
tent.
 
7 d after STZ injection, blood sugar levels of (NOD 
 
3 
 
B6)
F1 transgenic mice and their TRX-negative littermates were
measured with Glutest E (KDK Corp., Kyoto, Japan), whose
range of measurable blood glucose concentrations is between 40
and 500 mg/dl. 10 d after STZ treatment, pancreata were re-
moved from 6-h-fasted (NOD 
 
3 
 
B6) F1 transgenic mice and
their TRX-negative littermates. Pancreatic insulin was extracted
according to the acid ethanol method (43), and the extracted in-
sulin was dissolved in cold PBS. Insulin concentration was deter-
mined using a mouse insulin ELISA kit. Insulin content was indi-
cated as the amount of pancreatic insulin (in nanograms) divided
by the pancreatic wet weight (in milligrams).
 
Statistical Analysis.
 
Data were expressed as mean 
 
6 
 
SD or
mean 
 
6 
 
SEM. Statistical analysis was performed by Mann-Whit-
ney U test, unpaired 
 
t
 
 test, and Kaplan-Meier methods using Stat-
View version 4.5 for the Macintosh (Abacus Concepts Inc., Berke-
ley, CA).
 
Results
 
Transgenic Mice Overexpressing Human TRX.
 
The Ins-TRX
transgene containing a human TRX cDNA under the hu-
man insulin promoter (Fig. 1) was microinjected into fertil-
ized eggs of NOD mice to generate NOD transgenic mice.
In the F1 generation, PCR analysis of tail DNA showed
that the Ins-TRX transgene was inherited by three NOD
transgenic strains, lines 21, 48, and 90. The expression of
human TRX mRNA was detected exclusively in the pan-
creas of transgenic mice using RT-PCR analysis (Fig. 2).
For the quantification of human TRX expression, islets
were isolated from (NOD 
 
3 
 
B6) F1 transgenic mice,
which were produced by intercrossing female B6 mice
with male NOD transgenic mice of each strain. Western
blot analysis using a human TRX–specific mAb as probe
showed a high level of human TRX expression in the
transgenic islets of lines 21 and 90 (Fig. 3, 
 
top
 
). For this
analysis, 15 
 
m
 
g of islet protein was loaded on each lane. By
comparing the densities of these bands with those of
known amounts of recombinant human TRX (Fig. 3, 
 
top
 
),
the ratio of human TRX to total protein in the islets was
estimated to be 1.7 ng/
 
mg in both lines 21 and 90. Al-
Figure 2. RT-PCR analysis of Ins-TRX transgene expression in vari-
ous organs. RNA was extracted from the indicated organs of a transgenic
mouse (line 90; Tg) and its TRX-negative littermate (non-Tg). 31 and 27
cycles of the PCR procedure were performed to detect the mRNA of
human TRX (hTRX, top) and hprt (bottom), respectively. Samples were
resolved by electrophoresis on 2% agarose gels and stained with an ethid-
ium bromide solution.
Figure 3. Top, Western blot analysis of human TRX expression in
pancreatic islets. Pancreatic islets were isolated from 8-wk-old (NOD 3
B6) F1 mice and their nontransgenic littermates. Approximately 15 mg of
islet protein was loaded in each well. The amounts of human TRX in the
lysates of transgenic islets from lines 90 and 21 mice were densitometri-
cally estimated to be 25 ng on the imaging film exposed using an ECL de-
tection kit. Prolonged exposure of a film revealed a faint band of human
TRX in line 48 (data not shown). Bottom, Immunoblot analysis of the en-
dogenous TRX expression in islets and pancreas. The lysates of islets were
prepared from (NOD 3 B6) F1 transgenic mice (line 90), their TRX-
negative littermates, and BALB/c mice. The lysates of the pancreas were
prepared from a (NOD 3 B6) F1 transgenic mouse. These lysates were
subjected to Western blot analysis using mouse TRX–specific serum. 2.5
mg (a) and 5 mg (b) of protein were loaded for each sample. The imaging
film was exposed overnight.1448 Pancreatic b Cell Destruction by Oxidative Stress
though human TRX was not detectable in the islets of line
48, prolonged exposure of the membrane revealed a low-
level expression of human TRX in these mice (not
shown). The expression of endogenous murine TRX was
also examined by Western blot analysis using rabbit anti–
mouse TRX serum as the probe, which was not reactive
with human TRX. The levels of endogenous TRX ex-
pression were found to be much lower in the islets than in
the pancreas (Fig. 3, bottom).
Insulin Secretory Capacities of Transgenic Islets. We next ex-
amined whether transgenic TRX expression in b cells af-
fects glucose-responsive insulin secretion. The insulin
secretory capacities of (NOD 3 B6) F1 transgenic islets at
three glucose concentrations (5, 10, and 25 mM) were
0.40 6 0.05, 1.02 6 0.08, and 2.76 6 0.15 ng/h/islet
(mean 6 SD), respectively. The insulin secretory capacities
of their TRX-negative littermates were 0.43 6 0.03, 1.04 6
0.07, and 2.83 6 0.13 ng/h/islet, respectively. There was
no significant difference between the results from the islets
of transgenic mice and those of their TRX-negative litter-
mates at any glucose concentration (unpaired t test, NS for
all), indicating that the overexpression of TRX did not af-
fect the insulin secretory capacity of b cells.
Incidence of Diabetes. To examine the effect of TRX ex-
pression on the development of diabetes, female NOD
transgenic mice and their female TRX-negative littermates
were monitored for glucosuria up to 32 wk of age. In
transgenic mice of lines 21 and 90, the cumulative inci-
dence of diabetes was markedly reduced at 32 wk of age
(Fig. 4). Statistical analysis demonstrated a significant differ-
ence between NOD transgenic mice and their TRX-nega-
tive littermates (Kaplan-Meier method, P , 0.01 for both
lines). The incidence of diabetes was not significantly re-
duced in transgenic mice of line 48, in which the TRX ex-
pression was very low.
Insulitis Score. To determine whether TRX overex-
pression affects the development of insulitis in pancreatic
islets, we performed histochemical analyses to determine
the degree of the insulitis in NOD transgenic mice and
their TRX-negative littermates before the onset of overt
diabetes. The average insulitis scores of 12-wk-old female
NOD transgenic mice (line 90) and their female TRX-
negative littermates were 1.63 6 0.32 and 1.57 6 0.26
(mean 6 SEM), respectively, indicating that the transgenic
TRX overexpression does not attenuate the development
of insulitis.
Blood Glucose Levels and Insulin Content after STZ Injec-
tion. We next examined whether TRX overexpression
confers resistance to STZ-induced diabetes. In this experi-
ment, we used (NOD 3 B6) F1 transgenic mice and their
nontransgenic littermates to avoid the complications in in-
terpretation that could arise from the autoimmune diabetes
accompanying the NOD background. No evidence of in-
sulitis was observed in these mice. Before STZ treatment,
fasting blood glucose levels were 80.0 6 5.7 mg/dl for
transgenic mice (n 5 9) and 77.6 6 9.7 mg/dl for their
TRX-negative littermates (n 5 9). 7 d after STZ injection,
blood glucose levels were .500 mg/dl in most of the non-
transgenic mice, but were only moderately elevated in
TRX transgenic mice, as shown in Fig. 5 a. There was a
significant difference in blood glucose levels between the
transgenic mice and their TRX-negative littermates. We
Figure 4. Cumulative inci-
dence of diabetes in each NOD
transgenic strain. Mice were
monitored with weekly mea-
surements of urine glucose. The
number (n) of animals tested is
shown in each figure. Statistical
analysis demonstrated a signifi-
cant difference between trans-
genic mice and their nontrans-
genic littermates in lines 90 and
21 (Kaplan-Meier method, P ,
0.01 for both), but not in line 48
(NS).
Figure 5. Alteration of blood
glucose levels and insulin content
after STZ treatment. STZ (250
mg/kg) was injected intraperito-
neally into 8-wk-old (NOD 3
B6) F1 mice after an 18-h starva-
tion period. (a) 7 d after injec-
tion, the blood glucose concen-
tration was measured from mice
fed ad libitum. When the con-
centration surpassed 500 mg/dl,
the upper limit of measurement,
its value was indicated as .500
mg/dl. There was a significant
difference between (NOD 3
B6) F1 transgenic mice (line 90,
male; n 5 9) and their TRX-
negative littermates (male, n 5 9)
(Mann-Whitney U test, †P ,
0.05). (b) Pancreata were excised
from 6-h-starved (NOD 3 B6)
F1 transgenic mice (line 21, fe-
male; n 5 5) and their TRX-
negative littermates (female, n 5
5) 10 d after STZ injection. Pan-
creatic insulin contents of trans-
genic mice were significantly
higher than those of their TRX-
negative littermates (unpaired t
test,  §P  ,  0.05).1449 Hotta et al.
next examined the insulin content of the pancreas of STZ-
treated transgenic and nontransgenic littermates after sub-
jecting them to a 6-h fast (Fig. 5 b). Pancreatic insulin con-
tent was significantly higher in the transgenic mice (21.8 6
9.4 ng/mg pancreatic weight; n 5 5) than in their TRX-
negative littermates (8.2 6 4.2 ng/mg; n 5 5). Without
STZ treatment, insulin content was the same for the trans-
genic mice (66 6 7.0 ng/mg; n 5 5) and their TRX-nega-
tive littermates (63.0 6 8.6 ng/mg; n 5 5). These results
clearly indicate that human TRX overexpression protects
b cells from the cytotoxicity caused by STZ administration.
Discussion
IDDM is characterized by the infiltration of lymphocytes
into the pancreatic islets followed by the destruction of b
cells, which leads to overt diabetes. However, it is not well
understood how b cells are destroyed by the immunocytes
in islets. The coexistence of various cell types and their
complex interactions in the inflammatory islets make it
very difficult to study the mechanism of b cell destruction
in vivo. To overcome this complexity, we adopted a strat-
egy in which molecules that are assumed to affect b cell de-
struction are directly tested by overexpressing them specifi-
cally in b cells in vivo. In this study, we have generated
NOD transgenic mice that express human TRX, which
has strong antioxidative and antiapoptotic activity (20, 26).
Analysis by RT-PCR demonstrated that human TRX was
expressed exclusively in the islets of our transgenic mice.
Immunoblot analysis showed that the ratio of human TRX
to total protein of the transgenic islets was z1.7 ng/mg
(Fig. 3, top). The endogenous TRX levels of normal organs
are less than z0.3 ng/mg (J. Yodoi, unpublished data).
Therefore, the TRX levels in transgenic islets are consider-
ably higher than those of normal tissues. An excessive expres-
sion of TRX may be toxic to cells, as pointed out by Baker et
al. (44). However, we consider this an unlikely problem in
our transgenic mice because endogenous TRX expression is
often enhanced to 0.3–2 ng/mg or more (28, 45) in imma-
ture, transformed, or neoplastic cells (26–29, 44, 45).
The targeted overexpression of TRX in pancreatic b
cells remarkably reduced the incidence of diabetes (Fig. 4),
indicating a protective effect of TRX against the autoim-
mune destruction of b cells. Destruction of b cells induced
by the ROI-generating agent STZ was also attenuated by
TRX overexpression, as evidenced by lower blood glucose
levels and higher insulin content in TRX transgenic mice
than in their TRX-negative littermates. These results indi-
cate that the overexpression of the antioxidative molecule
TRX in b cells confers protective effects against spontane-
ous autoimmune diabetes as well as experimental diabetes
induced by STZ. Recently, Kubisch et al. (46) reported
that the overexpression of Drosophila Cu/Zn superoxide
dismutase, a superoxide-scavenging enzyme, in b cells con-
fers resistance to experimental diabetes induced by alloxan.
Taken together, these results strongly suggest that ROIs
play major roles in the b cell destruction that accompanies
not only experimental diabetes induced by the ROI-gener-
ating drugs STZ and alloxan, but also the spontaneous au-
toimmune diabetes of the NOD mouse.
Our study revealed that the expression of endogenous
TRX is very low in islet cells compared with pancreatic
exocrine cells (Fig. 3, bottom). Previously, Hansson et al.
(47) suggested that a lower expression of TRX occurs in is-
let cells than in pancreatic exocrine cells, although their
immunohistochemical analysis was not quantitative. They
also showed that TRX expression was suppressed in re-
cently fed mice. This attenuation of TRX expression in in-
sulin-secreting b cells may be one of the reasons b cells are
highly susceptible to oxidative stress. Recent studies have
indicated a stepwise development of autoimmune diabetes,
with insulitis the first phase and massive destruction of b
cells the second (48). We showed that there was no signifi-
cant difference in the severity of insulitis between NOD
transgenic mice and their TRX-negative littermates, indi-
cating that overexpression of TRX did not prevent insuli-
tis, but rather attenuated the cytotoxicity of the infiltrating
immunocytes in islets. This result is consistent with the
function of TRX as an antioxidative protein. It has also
been reported that IDDM develops without insulitis in
transgenic mice overexpressing inducible NO synthase
(iNOS) in b cells (49), probably through the increased oxi-
dative stress due to NO production. This report and our
present study together suggest that oxidative stress is one of
the major effector mechanisms of b cell destruction by in-
filtrating inflammatory cells.
Recently, apoptosis has also been suggested as a pivotal
mechanism of b cell destruction in autoimmune (10–13)
and drug-induced diabetes (14, 50). The Fas/FasL system
has been implicated in b cell apoptosis. NOD transgenic
mice that express FasL in their b cells were reported to be
highly susceptible to autoimmune diabetes (12), whereas
Fas-deficient NOD-lpr/lpr mice were resistant to autoim-
mune diabetes (12, 13). Recombinant TRX has been re-
ported to protect cells against apoptosis mediated by both
TNF and anti-Fas agonistic Ab (51). Very recently, mam-
malian TRX has been shown to function as a direct inhibi-
tor of apoptosis signal-regulating kinase (ASK)-1 (52).
These results suggest that the antiapoptotic function of
TRX may also participate in the protection of b cells after
immunocytic infiltration.
Although b cell–targeted overexpression of TRX effec-
tively suppressed the incidence of autoimmune diabetes in
NOD mice, a low percentage of transgenic mice still de-
veloped diabetes with significantly later onset. At present,
we can only speculate on the molecular mechanisms caus-
ing diabetes in these mice. It is probable that TRX could
not confer complete resistance to the oxidative stress and b
cell death caused by infiltrating cells. Alternatively, other
secondary mechanisms for b cell destruction, such as the
perforin-dependent cytotoxicity of CD81 T cells (53),
might have led to the autoimmune diabetogenic b cell loss.
In human IDDM, overt diabetes develops when b cells
are almost completely destroyed. Subjects at high risk for
the future development of IDDM can only be identified by
the presence of autoantibodies, which indicate the presence1450 Pancreatic b Cell Destruction by Oxidative Stress
of autoimmunity and probable ongoing b cell destruction.
The prevention of and intervention in IDDM is only possi-
ble during the second phase in the development of the au-
toimmune process. Therefore, these effects of TRX over-
expression suggest a new approach to protecting subjects in
the second phase of IDDM or to delaying the development
of overt diabetes.
This study provides the first direct evidence that an anti-
oxidative and antiapoptotic protein has protective effects
on autoimmune diabetes. Our results strongly suggest that
oxidative stress plays an essential role in b cell destruction
caused by inflammatory cells in islets. The results also sug-
gest an antioxidative and antiapoptotic strategy as a promis-
ing approach for the prevention of and intervention in
IDDM in particular, as well as other autoimmune diseases
in general, in subjects with ongoing autoimmunity.
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